Michael Lowe

Emory University — United States

Medicine · Health Sciences

36h-index7.6kcitations226works3.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cutaneous Melanoma Detection and Management(64), CAR-T cell therapy research(34), Cancer Immunotherapy and Biomarkers(28), Melanoma and MAPK Pathways(28), Immunotherapy and Immune Responses(19)

Publications191 total

Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma
Journal of Cancer Research and Clinical Oncology·2025Open Access
Commissioning of a gantry‐mounted synchrocyclotron for preclinical FLASH studies utilizing spread‐out Bragg peaks
Journal of Applied Clinical Medical Physics·2025· 1 citedOpen Access
527 Primary results with long-term follow up of a phase II study of neoadjuvant and adjuvant cemiplimab in high-risk resectable cutaneous squamous cell carcinoma
Regular and Young Investigator Award Abstracts·2025Open Access
22 Neoadjuvant pepinemab enhances immune checkpoint blockade in metastatic melanoma characterized by biomarkers of TME reprogramming including tertiary lymphoid structures
Regular and Young Investigator Award Abstracts·2025Open Access
Gene Expression Profile–Based Test to Predict Melanoma Sentinel Node Status
JAMA Surgery·2025· 4 citedOpen Access
A pooled analysis of clinical outcomes with anti-PD1-based neoadjuvant immunotherapy (NeoIT) in cutaneous squamous cell carcinoma (cSCC).
Journal of Clinical Oncology·2025
Lymph node excision (LNEx) for patients with stage III melanoma with one clinically positive node: Excision of Lymph Node trial (EXCILYNT).
Journal of Clinical Oncology·2025
Abstract 3975: Regulating dendritic cells to promote mature tertiary lymphoid structures and enhance anti-tumor immunity
Cancer Research·2025
Abstract 6007: Neoadjuvant pepinemab enhances DC function associated with mature tertiary lymphoid structures and activity of immune checkpoint blockade in patients with metastatic melanoma
Cancer Research·2025
Combination radiation and αPD-L1 enhance tumor control by stimulating CD8+ PD-1+ TCF-1+ T cells in the tumor-draining lymph node
Nature Communications·2025· 10 citedOpen Access
An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma
Annals of Surgical Oncology·2025· 6 citedOpen Access
The Landmark Series: Melanoma and Adjuvant Therapy
Annals of Surgical Oncology·2025· 2 cited
Toward Functional Biomarkers of Response to Neoadjuvant Oncolytic Virus in Stage II Melanoma: Immune-Förster Resonance Energy Transfer and the Dynamic Tumor Immune Microenvironment
JCO oncology advances.·2025· 4 citedOpen Access
Prospective multicenter evaluation of a clinicopathologic and gene expression profile test to predict sentinel node status in T1-T3 cN0 melanoma: updated MERLIN_001 trial
EJC Skin Cancer·2025· 2 citedOpen Access
HSD5 Real-World Survey on Treatment Pathways and Patterns for Patients With Primary Immune Complex Membranoproliferative Glomerulonephritis
Value in Health·2024
1307 Mitochondrial regulator REXO2 is essential for the potent anti-tumor stem memory T cells
Regular and Young Investigator Award Abstracts·2024Open Access
747 Pepinemab a semaphorin 4D blockade antibody in combination with immune checkpoint therapies induces mature lymphoid aggregates correlating with clinical outcomes
Regular and Young Investigator Award Abstracts·2024Open Access
466 Th17 polarization generates high quality resident memory-like TIL from patients with advanced melanoma
Regular and Young Investigator Award Abstracts·2024Open Access
695 Phase 2 study of nivolumab and ipilimumab in combination with sirolimus and prednisone in kidney transplant recipients with selected unresectable or metastatic cutaneous cancers
Regular and Young Investigator Award Abstracts·2024Open Access
The association of azole antifungals with overall survival in patients with non-small cell lung cancer receiving immune checkpoint inhibitors
The Oncologist·2024· 1 citedOpen Access
page 1 of 10Next →

Frequent Co-authors

Jonathan S. Zager(11), Keith A. Delman(9), Vernon K. Sondak(6), James Sun(6), Georgia M. Beasley(6), Khandan Keyomarsi(5), John F. Thompson(5), Alexander C. J. van Akkooi(5), Clara R. Farley(5), David Gyorki(4), Tina J. Hieken(4), Matthew Perez(4), Amod A. Sarnaik(4), David W. Ollila(4), Giorgos C. Karakousis(4), Dale Han(4), Norma E. Farrow(4), Ragini R. Kudchadkar(4), Mohammad K. Khan(4), Merrick I. Ross(3)